张 娟,杨历新

原发性骨质疏松症(osteoporosis，OP)是最常见的骨髓疾病，以骨量减少、骨组织的显微结构受损，以松质骨骨小梁变细、断裂、数量减少、皮质骨多孔和变薄为特征。骨质疏松症的患病率逐年提高，已成为重要的公共健康问题。OPG/RANK/RANKL作为经典骨代谢通路，在骨质疏松症中发挥重要作用。下文我将从OPG/RANK/RANKL通路调控骨质疏松症方面的进行综述，为临床早期预防骨质疏松症提供思路。

OPG/RANK/RANKL；骨质疏松症

[1] Datta H K,Ng W F,Walker J A,et al.The cell biology of bone metabolism[J].Journal of Clinical Pathology,2008,61(5):577–587. [2] Wang J,Zhao B,Che J,et al.Hypoxia Pathway in Osteoporosis:Laboratory Data for Clinical Prospects[J].Int J Environ Res Public Health,2023,20(4):3129. [3] Spartalis M,Kasimatis E,Liakou E,et al.Serum OPG and RANKL Levels as Risk Factors for the Development of Cardiovascular Calcifications in End-Stage Renal Disease Patients in Hemodialysis[J].Life(Basel,Switzerland),2023,13(2):454. [4] Atilano-Miguel S,Barbosa-Cortés L,Ortiz-Muñiz R.Duchenne muscular dystrophy:RANK/RANKL/OPG(receptor activator of nuclear factor-kB/RANK ligand/osteoprotegerin)system and glucocorticoids[J].Bol Med Hosp Infant Mex,2022,79(5):275–283. [5] Yang H,Liu W,Zhou X,et al.The association between RANK,RANKL and OPG gene polymorphisms and the risk of rheumatoid arthritis:a case-controlled study and meta-analysis[J].Bioscience Reports,2019,39(6):BSR20182356. [6] Pan K-Q,Zhang P-M,Deng J,et al.[Expression of OPG/RANK/RANKL in the rat dental pulp tissue of periodontitis combined with vascular calcification and its clinical significance][J].Shanghai Kou Qiang Yi Xue,2016,25(4):391–395. [7] NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis,and Therapy.Osteoporosis prevention,diagnosis,and therapy[J].JAMA,2001,285(6):785–795. [8] NIH Consensus Development Panel on Osteoporosis Prevention,Diagnosis,and Therapy,March 7-29,2000:highlights of the conference[J].Southern Medical Journal,2001,94(6):569–573. [9] 中华医学会骨质疏松和骨矿盐疾病分会,章振林.原发性骨质疏松症诊疗指南（2022）[J].中国全科医学,2023,26(14):1671–1691. [10] Kiechl S,Werner P,Knoflach M,et al.The osteoprotegerin/RANK/RANKL system:a bone key to vascular disease[J].Expert Rev Cardiovasc Ther,2006,4(6):801–811. [11] Boyce B F,Xing L.Biology of RANK,RANKL,and osteoprotegerin[J].Arthritis Research&Therapy,2007,9 Suppl 1(Suppl 1):S1. [12] Kovács B,Vajda E,Nagy E E.Regulatory Effects and Interactions of the Wnt and OPG-RANKL-RANK Signaling at the Bone-Cartilage Interface in Osteoarthritis[J].Int J Mol Sci,2019,20(18):4653. [13] Bai P,Sun Y,Jin J,et al.Disturbance of the OPG/RANK/RANKL pathway and systemic inflammation in COPD patients with emphysema and osteoporosis[J].Respiratory Research,2011,12(1):157. [14] 赵希云,张晓刚,宋敏，等.OPG/RANK/RANKL通路在骨质疏松与动脉粥样硬化相关性中的作用机制研究进展[J].中国动脉硬化杂志,2016,24(12):1273–1278. [15] Wada T,Nakashima T,Hiroshi N,et al.RANKL-RANK signaling in osteoclastogenesis and bone disease[J].Trends Mol Med,2006,12(1):17–25. [16] Nelson C A,Warren J T,Wang M W-H,et al.RANKL employs distinct binding modes to engage RANK and the osteoprotegerin decoy receptor[J].Structure,2012,20(11):1971–1982. [17] Ono T,Hayashi M,Sasaki F,et al.RANKL biology:bone metabolism,the immune system,and beyond[J].Inflamm Regen,2020,40:2. [18] Weitzmann M N.Bone and the Immune System[J].Toxicologic Pathology,2017,45(7):911–924. [19] Baud’huin M,Lamoureux F,Duplomb L,et al.RANKL,RANK,osteoprotegerin:key partners of osteoimmunology and vascular diseases[J].Cell Mol Life Sci,2007,64(18):2334–2350. [20] Udagawa N,Koide M,Nakamura M,et al.Osteoclast differentiation by RANKL and OPG signaling pathways[J].J Bone Miner Metab,2021,39(1):19–26. [21] Liu Y,Wang C,Wang G,et al.Loureirin B suppresses RANKL-induced osteoclastogenesis and ovariectomized osteoporosis via attenuating NFATc1 and ROS activities[J].Theranostics,2019,9(16):4648–4662. [22] Boyce B F,Xing L.Biology of RANK,RANKL,and osteoprotegerin[J].Arth Res&Ther,2007,9(Suppl 1):S1. [23] Horowitz M C,Fretz J A,Lorenzo J A.How B cells influence bone biology in health and disease[J].Bone,2010,47(3):472–479. [24] Hienz S A,Paliwal S,Ivanovski S.Mechanisms of Bone Resorption in Periodontitis[J].J Immunol Res,2015,2015:615486. [25] Hodge J M,Collier F M,Pavlos N J,et al.M-CSF potently augments RANKL-induced resorption activation in mature human osteoclasts[J].PloS One,2011,6(6):e21462. [26] Lee D-W,Kwon J-Y,Kim H-K,et al.Propofol attenuates osteoclastogenesis by lowering RANKL/OPG ratio in mouse osteoblasts[J].Int J Sci,2018,15(7):723–729. [27] Yahiro Y,Maeda S,Morikawa M,et al.BMP-induced Atoh8 attenuates osteoclastogenesis by suppressing Runx2 transcriptional activity and reducing the Rankl/Opg expression ratio in osteoblasts[J].Bone Research,2020,8(1):32. [28] Boyce B F,Xing L.Functions of RANKL/RANK/OPG in bone modeling and remodeling[J].Arch Biochem Biophys,2008,473(2):139–146. [29] Hofbauer L C,Khosla S,Dunstan C R,et al.The roles of osteoprotegerin and osteoprotegerin ligand in the paracrine regulation of bone resorption[J].J Bone Miner Res,2000,15(1):2–12. [30] Udagawa N,Takahashi N,Yasuda H,et al.Osteoprotegerin produced by osteoblasts is an important regulator in osteoclast development and function[J].Endocrinology,2000,141(9):3478–3484. [31] Liu J-Z,Ji Z-L,Chen S-M.[The OPG/RANKL/RANK system and bone resorptive disease][J].Sheng Wu Gong Cheng Xue Bao,2003,19(6):655–660. [32] Kim N,Odgren P R,Kim D K,et al.Diverse roles of the tumor necrosis factor family member TRANCE in skeletal physiology revealed by TRANCE deficiency and partial rescue by a lymphocyte-expressed TRANCE transgene[J].Proc Natl Acad Sci U S A,2000,97(20):10905–10910. [33] Papadopouli A E,Klonaris C N,Theocharis S E.Role of OPG/RANKL/RANK axis on the vasculature[J].Histology and Histopathology,2008,23(4):497–506. [34] Chi G,Qiu L,Ma J,et al.The association of osteoprotegerin and RANKL with osteoporosis:a systematic review with meta-analysis[J].J Orthop Surg Res,2023,18(1):839. [35] Kostenuik P J.Osteoprotegerin and RANKL regulate bone resorption,density,geometry and strength[J].Curr Opin Pharmacol,2005,5(6):618–625. [36] Kong S H.Denosumab,an effective osteoporosis treatment option for men[J].Korean J Intern Med,2022,37(5):947–948. [37] Yanbeiy Z A,Hansen K E.Denosumab in the treatment of glucocorticoid-induced osteoporosis:a systematic review and meta-analysis[J].Drug Des Devel Ther,2019,13:2843–2852. [38] Manzaneque A,Chaguaceda C,Mensa M,et al.Use and safety of denosumab in cancer patients[J].J Clin Ph,2017,39(3):522–526. [39] Delmas P D.Clinical potential of RANKL inhibition for the management of postmenopausal osteoporosis and other metabolic bone diseases[J].J Clin Densitom,2008,11(2):325–338. [40] Kendler D L,Cosman F,Stad R K,et al.Denosumab in the Treatment of Osteoporosis:10 Years Later:A Narrative Review[J].Adv Ther,2022,39(1):58–74. [41] Hattori K,Takahashi N,Kojima T,et al.Risk factors for denosumab discontinuation in patients with postmenopausal osteoporosis[J].Mod Rheumatol,2023,33(4):843–850. [42] Tsourdi E,Langdahl B,Cohen-Solal M,et al.Discontinuation of Denosumab therapy for osteoporosis:A systematic review and position statement by ECTS[J]Bone,2017;105:11-17.

点击下载PDF